The results represent the evolution of sales of drugs produced in Bucharest, and not those imported from other factories.
The company’s income dropped in Q1 2008 to RON 48.44 million (€13.2 mln), from RON 71.15 mln (€21.5 mln) in the same period in 2007, according to a company release.
